AstraZeneca and Cleveland Clinic Abu Dhabi Launch $50 Million Clinical Trials Initiative

Global biopharmaceutical leader AstraZeneca is set to invest $50 million in Abu Dhabi to conduct numerous clinical trials, marking a significant partnership with Cleveland Clinic Abu Dhabi. This collaboration aims to tackle critical healthcare challenges, with the initial studies slated to commence before the year's end. Over the next few years, approximately 30 trials will be carried out in the emirate, focusing on advancing treatments for cardiovascular, renal, and metabolic diseases. Cardiovascular disease accounts for 34 percent of all deaths in the UAE, underscoring the urgent need for enhanced medical care, according to the UAE Ministry of Health and Prevention.

Iskra Reic, international executive vice president for AstraZeneca, stated at the Abu Dhabi Future Health Summit that the investment amounts to approximately $50 million over the coming years. She confirmed that feasibility work for six studies has been finalized, with the first expected to launch by year-end. This initiative, supported by the Abu Dhabi Department of Health, is anticipated to benefit patients and the broader medical community in the capital.

The expansion of clinical research in Abu Dhabi is expected to increase patient inclusion in global clinical trials, enhance the collection of data pertinent to the local population and healthcare system, and foster greater connection for local researchers and healthcare professionals within the global clinical research network. Ms. Reic emphasized that this benefits both researchers and patients.

In parallel, AstraZeneca announced a global collaboration with Oracle. The first program in Abu Dhabi will concentrate on hypertension care and clinical research with M42, leveraging AI and real-world data for earlier diagnosis, clinical trial recruitment, and safety monitoring. Ms. Reic highlighted that these partnerships combine clinical development and healthcare expertise with AI and technological advancements to improve patient outcomes and support more sustainable and resilient healthcare systems.

The goal is to utilize available data and AI for quicker disease identification, enabling earlier intervention and improved patient care. Ms. Reic explained that successful early detection of hypertension could lead to identifying at-risk individuals sooner, allowing for timely treatment and better outcomes. Both partnerships are designed to support local patients and the healthcare system.

Ms. Reic identified the UAE as an ideal partner due to its robust data collection, research network, and governmental commitment to the health sector. She noted the UAE's well-connected medical records and Emirati genomic data, combined with AI, allow for disease prediction. The presence of engaged regulators and a knowledgeable clinical research and academic network creates a nearly perfect ecosystem for innovation.

Early detection and treatment can improve patient outcomes and enhance the financial sustainability of healthcare systems. Ms. Reic argued that late treatment is detrimental to both patients and healthcare system finances, whereas early intervention can free up funding for investment and innovation.

The role of the pharmaceutical industry is evolving with advancements in AI, health data, and technology. Ms. Reic stated that the future involves transforming patient care beyond just developing and delivering medicines, requiring a focus on every step of the patient pathway to reduce barriers and enable earlier intervention. She stressed the necessity of collaboration among companies, governments, hospitals, and research organizations, asserting that no single entity can transform the healthcare system alone.